SMS Pharmaceuticals Limited AI Stock Analysis
Want to see IN:SMSPHARMA full AI Analyst Report?
SMS Pharmaceuticals Limited (SMSPHARMA) AI Stock Analysis
SMS Pharmaceuticals Limited
(NSE:SMSPHARMA)
The overall score of 62 reflects a company with a solid financial foundation and strong positive price momentum, offset by significant concerns. The primary strength is the robust balance sheet and bullish technical trend, with the stock trading above all key moving averages. However, the major risks are persistently weak cash flow generation and a high valuation (P/E of 39.4), which leaves little room for error. The company is in an investment phase, and its success hinges on translating spending into improved cash flows and margins.
SMS Pharmaceuticals Limited (SMSPHARMA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 45.51B
- Dividend Yield
- 0.08%
- Average Volume (3M)
- 39.71K
- Price to Earnings (P/E)
- 38.5
- Beta (1Y)
- 1.13
- Revenue Growth
- 12.96%
- EPS Growth
- 32.16%
- Country
- India
- Employees
- 1,617
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
SMS Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of AP...
SMS Pharmaceuticals Limited Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong (Score 85) with low debt-to-equity of 0.25, but cash flow is weak (Score 42) with persistent negative free cash flow. The income statement (Score 62) shows moderate growth and profitability recovery, though margin volatility and a past loss are concerns. The overall financial picture is stable but constrained by poor cash conversion.
Income Statement
62PositiveBalance Sheet
85Very PositiveCash Flow
42Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.73B | 8.87B | 7.83B | 7.09B | 5.22B | 5.15B |
| Gross Profit | 2.73B | 1.75B | 1.45B | 2.11B | 1.29B | 1.81B |
| EBITDA | 1.97B | 1.71B | 1.45B | 1.18B | 593.89M | 1.20B |
| Net Income | 1.17B | 1.02B | 691.36M | 498.26M | -70.59M | 622.20M |
Balance Sheet | ||||||
| Total Assets | 14.61B | 13.62B | 11.53B | 10.34B | 8.80B | 8.60B |
| Cash, Cash Equivalents and Short-Term Investments | 363.13M | 460.75M | 415.86M | 361.16M | 73.78M | 465.83M |
| Total Debt | 3.49B | 3.65B | 3.11B | 2.81B | 2.54B | 2.63B |
| Total Liabilities | 6.18B | 5.77B | 5.13B | 4.98B | 4.19B | 3.89B |
| Stockholders Equity | 8.43B | 7.86B | 6.40B | 5.36B | 4.61B | 4.70B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -926.46M | -588.57M | -20.35M | -74.71M | 129.86M |
| Operating Cash Flow | 0 | 379.12M | 645.23M | 501.25M | 224.50M | 402.34M |
| Investing Cash Flow | 0 | -1.32B | -1.24B | -520.72M | -296.86M | -271.53M |
| Financing Cash Flow | 0 | 981.46M | 644.32M | 306.79M | -319.69M | -69.21M |
SMS Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSPHARMA, the sentiment is Positive. The current price of 486.65 is above the 20-day moving average (MA) of 482.48, above the 50-day MA of 458.58, and above the 200-day MA of 398.96, indicating a bullish trend. The MACD of 15.94 indicates Positive momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 22.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SMSPHARMA.
SMS Pharmaceuticals Limited Peers Comparison
Overall Rating
IN:GLAND76Outperform
IN:MARKSANS69Neutral
IN:SENORES63Neutral
IN:SMSPHARMA62Neutral
IN:KOPRAN60.3Neutral
IN:NGLFINE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | INR 536.16B | 43.32 | ― | 0.62% | 21.90% | 56.28% | |
| 69Neutral | INR 138.58B | 24.77 | ― | 0.29% | 24.20% | 59.18% | |
| 63Neutral | INR 52.45B | 37.35 | ― | ― | 39.71% | 53.21% | |
| 62Neutral | INR 45.58B | 38.49 | ― | 0.08% | 12.96% | 32.16% | |
| 60Neutral | INR 13.22B | 33.50 | ― | 1.10% | 34.11% | 123.11% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 46Neutral | INR 17.67B | 27.53 | ― | 0.06% | 40.66% | 208.52% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SMSPHARMA | SMS Pharmaceuticals Limited | 486.65 | 203.89 | 72.11% | |
| IN:GLAND | Gland Pharma Ltd. | 3249.25 | 1490.76 | 84.77% | |
| IN:KOPRAN | Kopran Limited | 273.50 | 142.72 | 109.13% | |
| IN:MARKSANS | Marksans Pharma Limited | 305.80 | 117.27 | 62.20% | |
| IN:NGLFINE | NGL Fine-Chem Ltd. | 2859.95 | 1506.61 | 111.33% | |
| IN:SENORES | Senores Pharmaceuticals Ltd. | 1138.85 | 347.10 | 43.84% |
SMS Pharmaceuticals Limited Corporate Events
SMS Pharmaceuticals wins tax appeal; Rs 45.63 crore demand vacated
SMS Pharmaceuticals Limited has announced that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has allowed its appeal against an income tax assessment order for Assessment Year 2023-24. The appellate order under Section 250...
SMS Pharmaceuticals’ tax appeal dismissed; reduced demand upheld
SMS Pharmaceuticals Limited has disclosed that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has dismissed the company’s appeal against an earlier assessment order for the 2018-19 financial year. The case stems from a tax...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026
